Complementing cell lines

Details Complementing cell lines Complementing cell lines

2005-03-22

2005-03-22

Foley, Shannon (Department: 1648)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S041000, C435S069100, C435S235100

Reexamination Certificate

active

06869794

ABSTRACT:
A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.

REFERENCES:
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: WO 9613598 (1996-05-01), None
patent: WO 9626281 (1996-08-01), None
Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.
Basler et al., Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, 1996, Gene 170, pp. 249-254.
Chiu et al., Folding & Design, “Optimizing energy potentials for success in protein tertiary structure prediction,” May 1998, vol. 3, pp. 223-228.
Gurunathan et al., American Association of Immunologists, “CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Induces Protective Immunity to Infectious and Tumor Challenge,” 1998, vol. 161, pp. 4563-4571.
Jolly, Viral vector systems for gene therapy, 1994, Cancer Gene Therapy, vol. 1, No. 1, pp. 51-64.
Merriam-Webster Dictionary (on line) retrieved from the internet<URL:http://www.m-w.com/cgi-bin/dictionary, “derive,” 2002.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” 1994, Merz et al. (editors), Birkhauser, Boston, MA, pp. 433 and 492-495.
Stevenson et al., Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein, 1997, Journal of Virology, vol. 71, pp. 4782-4790.
Verma et al., Nature, “Gene therapy-promises, problems and prospects,” Sep. 1997, vol. 389, pp. 239-242.
Abrahamsen et al., Construction of an Adenovirus Type 7a E1A- Vector, Journal of Virology, 1997, pp. 8946-8951, vol. 71, No. 11.

Affiliated with

Also associated with

Rating

Complementing cell lines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Complementing cell lines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complementing cell lines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3423092